CancerPACT Cancer Patients Alliance for Clinical Trials

Transcription

1 TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Cancer Clinical Trials in the Sacramento Area Summer 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.3 3. Gastrointestinal p.3 4. Gynecologic p.4 5. Head & Neck p.5 6. Lung p.5 7. Melanoma p.6 8. Mesothelioma p.6 9. Prostate p Sarcoma p Urologic p.7 II. Hematologic Cancers 1. Leukemia p.8 2. Lymphoma p.8 3. Myeloma p.9 III. Other Solid Tumors p.9 I. Solid Tumors 1. Breast Cancer 1. A Phase III Study of SU in Combination with Paclitaxel Versus Bevacizumab with Paclitaxel in the First-Line Advanced Disease Setting in Patients Having Breast Cancer 2. CALGB Phase III Randomized Study of Cyclophosphamide and Doxorubicin (CA) (4 vs. 6 Cycles) Versus Paclitaxel (4 vs. 6 Cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes: A 2X2 Factorial UC Davis Cancer Center ; Sutter Cancer Center (SCC)

2 2 3. CTSU CALGB Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant with or without Lapatinib (GW572016) for Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer 4. MAP.3 Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer 5. RTOG 0413/NSABP B-39 Randomized Phase III Study of Conventional Whole Breast Irradiation Versus Partial Breast Irradiation For Women With Stage 0, I, or II Breast Cancer 6. S0221 Phase III Trial of Continuous Schedule AC + G vs. Q2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer (UCD; SCC) 7. S0226 Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer 8. Phase III Trial Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer 9. Genentech AVF3693g Phase III, Multicenter, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination with Chemotherapy Regimens in Subjects with Previously Treated Metastatic Breast Cancer (MGH) 10. CZOL446E2352 Prospective, Randomized, Double-Blind, Stratified, Placebo-Controlled, Multi-Center, 3-Arm Trial of the Continued Efficacy and Safety of Zometa (Every 4 Weeks vs. Every 12 Weeks vs. Placebo) in Patients with Documented Bone Metastases From Breast Cancer 11. NSABP B-37 Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco- Regional Relapse of Breast Cancer (UCD; SCC) 12. S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer 13. S0500 Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment 14. IBCSG Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemustane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (MGH) 15. PHII-87 Phase I/II Study of a Combination of Suberoylanilide Hydroxyalmic Acid (Vorinostat) Plus Paclitaxel and Bevacizumab in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent Breast Cancer (NCI# 7703) ( UCD) 16. NSABP B-42 Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer (SCC) 17. NUO7B1 Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Paclitaxel in Patients with Locally Recurrent or Metastatic Breast Cancer (NU-07B1) (SCC) 18. NSABP B-36 Clinical Trial of Adjuvant Therapy Comparing Six Cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) to Four Cycles of Adriamycin and Cyclophosphamide (AC) in Patients with Node Negative Breast Cancer (SCC) 19. S0622 Phase II Studies of Two Different Schedules of Dasatinib (NSC ) in Bone- Metastasis Predominant Metastatic Breast Cancer 20. CTSU PACCT-1 The TAILORx Trial: Program for the Assessment of Clinical Cancer Tests (PAACT-1): Trial Assigning Individualized Options for Treatment Endocrine Responsive Breast Cancer (UCD, SCC) 21. UCDCC#186 Serum Glycan Analysis in Breast Cancer UC Davis Cancer Center ; Sutter Cancer Center (SCC)

3 3 22. GSK-EGF Open-Label, Multicenter Study of Lapatinib in Combination with Chemotherapy in Patients with ErbB2 Overexpressing Breast Cancer after Trastuzumab Failure in the Neoadjuvant or Adjuvant Setting (MGH) 23. MAP.3Bone Effects of Exemestane on Bone Strength in Postmenopausal Women at Increased Risk of Developing Breast Cancer 2. Central Nervous System Tumors 1. RTOG 0525 Phase III Trial comparing Conventional Adjuvant Temozolomide with Dose- Intensive Temozolmide in Patients with Newly Diagnosed Glioblastoma 2. NTI 0303 Phase III Randomized, Double Blind, Dexamethasone-Sparing Study Comparing Human Corticotropin-Releasing Factor (hcrf) to Placebo for Control of Symptoms Associated with Peritumoral Brain Edema in Patients with Malignant Brain Tumor Who Require Chronic Administration of High-Dose Dexamethasone 3. RTOG 0320 Phase III Trial Comparing Whole Brain Radiation and Stereotactic Radiosurgery Alone Versus With Temozolomide or Erlotinib in Patients With Non-Small Cell Lung Cancer and 1-3 Brain Metastases 4. ACNS0332 Phase III Trial to Determine Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients 5. UCDCC#208 Phase II Study of Bevacizumab (Avastin) and BCNU for Treatment of Relapsed, High Grade Gliomas 3. Gastrointestinal Cancers A. Colorectal Cancer 1. CTSU E5202 Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers 2. N0147 Randomized Phase III Trial of Oxaliplatin (OXAL) plus 5-Fluorouracil (5- FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer 3. Adventrx Phase III Multi-Center, Randomized Clinical Trial to Evaluate the Safety and Efficacy of Cofactor and 5-FU plus Bevacizumab vs. Leucovorin and 5-FU plus Bevacizumab as Initial Treatment for Metastatic Colorectal Cancer (MGH) 4. CTSU CALGB/SWOG C80405 Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5-FU / Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum 5. CTSU E5204 Phase III Intergroup Randomized Study of Postoperative Oxaliplatin, 5- Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation 6. S0600 Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC ) with or without Bevacizumab (NSC ) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with either FOLFOX, OPTIMOX or XELOX. (SCCC) UC Davis Cancer Center ; Sutter Cancer Center (SCC)

4 4 7. CTSU NSABP R-04 Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with Preoperative Radiation Therapy and Continuous Intravenous Infusion (CVI) of 5- Fluorouracil (5-FU) in the Treatment of Patients with Operable Carcinoma of the Rectum 8. ACOSOG Z6041 Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for ut2un0 Rectal Cancer B. Esophageal Cancer 1. S0356 Phase II Trial Oxaliplatin Plus Protracted Infusion 5-Flourouracil and Radiation for Potentially Curable Esophageal Cancer: A Phase II Trial With Molecular Correlates. C. Liver Cancer 1. PHII-83 Phase II Trial of Dasatinib (BMS ) in Advanced Hepatocellular Carcinoma 4. Gynecologic Cancers A. Cervical Cancer 1. GOG 0219 Phase III Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIB, IIIB, and IVA Cervical Carcinoma Limited to the Pelvis 2. RTOG 0418 Phase II Study of Intensity Modulated Radiation Therapy (IMRT) to the Pelvis +/- Chemotherapy for Post-operative Patients with Either Endometrial or Cervical Carcinoma 3. RTOG 0417 Phase II Study of Bevacizumab in Combination with Definitive Radiotherapy and Cisplatin Chemotherapy in Untreated Patients with Locally Advanced Cervical Carcinoma B. Ovarian/Peritoneal Cancer 1. GOG 0218 Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab in Women with Newly Diagnosed, Previously Untreated, Suboptimal Advanced Stage Epithelial Ovarian and Primary Peritoneal Cancer ( UCD; SCC) 2. GOG 0212 Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND# 70177), Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian or Primary Peritoneal Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy 3. CEPO906A2303 Randomized, Parallel Group, Open-Label, Active Controlled, Multicenter Phase III Trial of Patupilone (EPO906) Versus Pegylated Liposomal Doxorubicin (Doxil /Caelyx ) in Taxane/Platinum Refractory/Resistant Patients with Recurrent Epithelial Ovarian, Primary Fallopian or Primary Peritoneal Cancer UC Davis Cancer Center ; Sutter Cancer Center (SCC)

5 5 4. UCDCC#183 Clinical Protocol to Evaluate Glycans Analysis As a Diagnostic Test for Ovarian Cancer C. Uterine Cancer 1. GOG 0209 Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients with Stage III and IV or Recurrent Endometrial Cancer 2. RTOG 0418 Phase II Study of Intensity Modulated Radiation Therapy (IMRT) to the Pelvis +/- Chemotherapy for Post-operative Patients with Either Endometrial or Cervical Carcinoma 5. Head & Neck Cancer 1. RTOG 0522 Phase III Randomized Trial of Concurrent Accelerated Radiation and Cisplatin vs. Concurrent Accelerated Radiation, Cisplatin and Cetuximab (C225) [Followed by Surgery for Selected Patients] For Stage III and IV Head and Neck Carcinomas 2. RTOG 0615 Phase II Study of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy (3D-CRT) or Intensity-Modulated Radiation Therapy (IMRT) + Bevacizumab (BV) For Locally or Regionally Advanced Nasopharangeal Cancer 6. Lung Cancer 1. CALGB Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small ( 2 cm) Peripheral Non-Small Cell Lung Cancer 2. E5597 Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer (UCD, MGH) 3. RTOG 0320 Phase III Trial Comparing Whole Brain Radiation and Stereotactic Radiosurgery Alone Versus With Temozolomide or Erlotinib in Patients With Non-Small Cell Lung Cancer and 1-3 Brain Metastases 4. E1505 Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC) (UCD, SCC) 5. GENENTECH AVF3671g Phase III Randomized, Double Blind, Placebo-Controlled Trial Comparing Bevacizumab Therapy with or without Erlotinib after Completion of Chemotherapy with Bevacizumab for the First Line Treatment of Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (MGH) 6. DO410 Phase III National Web-Based Randomized Study of Erlotinib or Placebo Following Concurrent Docetaxel, Carboplatin and Thoracic Radiotherapy in Patients with Inoperable Stage III Non-Small Cell Lung Cancer (MGH) 7. GlaxoSmithKline Phase II Study of Weekly Intravenous Hycamtin and Carboplatin as First- Line Treatment of Chemonaive Subjects with Extensive Small Cell Lung Cancer (MGH) 8. PHII-70 Phase II Randomized Trial of Sequential Versus Concurrent Docetaxel and PS-341 in Previously Treated Non-Small Cell Lung Cancer 9. Phase II Study of Vorinostat or Placebo in Combination with Carboplatin and Paclitaxel for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NCI #7863) UC Davis Cancer Center ; Sutter Cancer Center (SCC)

6 6 10. PHII-57 Phase II Study of Bortezomib (PS-341) for Patients With Advanced Bronchoalveolar Carcinoma (BAC) (NCI#7003) 11. S0526 Phase II Trial of Pemetrexed in Patients with Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) 12. M Open-Label, Randomized, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) 13. M Phase I/IIA Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies 14. UCDCC#128 Phase I/II Study of Docetaxel and OSI-774 in Solid Tumor Patients with an Emphasis on NSCLC Using Molecular Correlates As Potential Markers of Response 15. UCDCC#185 Phase I/II Trial of Abraxane TM (ABI-007) and ALIMTA (Pemetrexed) in Advanced Solid Tumors with Emphasis on Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer 16. UCDCC#177 Phase I/II Study of Erlotinib (TARCEVA) and Cetuximab (ERBITUX) in Advanced Solid Tumors with an Emphasis on Non-Small Cell Lung Cancer 17. S0429 Phase I Pilot Study of Weekly Docetaxel and Cetuximab Chemoradiation for Poor Risk Stage III Non-Small Cell Lung Cancer 18. S0533 Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC ) in Three Cohorts of Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer 19. S0424 Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men (UCD, MGH) 20. S9925 Ancillary, Lung Cancer Specimen Repository Protocol 7. Melanoma 1. PHII-77 Phase II Study Evaluating the Efficacy of VEGF Trap in Patients with Recurrent Inoperable Stage III or Stage IV Melanoma (NCI #7522) 2. S0438 Phase II Trial of BAY (Sorafenib; NSC ) with Either CCI-779 (Temsirolimus: NSC ) or R (Tipifarnib: NSC ) in Metastatic Melanoma 8. Mesothelioma 1. PHII-65 Phase II Study of Novel Oral Anti-Angiogenic Agent AZD2171 (NSC ) in Malignant Pleural Mesothelioma 9. Prostate Cancer 1. S9346 Phase III Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer 2. RTOG 0415 Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT in Patients with Favorable Risk Prostate Cancer UC Davis Cancer Center ; Sutter Cancer Center (SCC)

7 7 3. RTOG 0521 Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMART vs. Androgen Suppression (AS) and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer 4. RTOG P0126 Phase III Randomized Study of High Dose 3D-CRT Versus Standard Dose 3D-CRT in Patients Treated for Localized Prostate Cancer 5. S0421 Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer 6. PHII-84 Phase II Study of GW (Pazopanib) in Stage D0 Relapsed Androgen Sensitive Prostate Cancer Following Limited GnRH Agonist Therapy (NCI #7659) 7. UCDCC#182 Phase II Trial of Daily, Oral Gleevec (Imatinib Mesylate,STI571) in Combination with Every-Three-Week Intravenous Docetaxel in Patients with Metastatic Hormone-Refractory Prostate Cancer 10. Sarcoma 1. ARST0431 Phase III Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients with High-Risk Rhabdomyosarcoma 2. ARST0531 Phase III Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS) 3. AOST0221 Phase II Study of Aerosolized GM-CSF (NSC# , IND # 11042) in Osteosarcoma Patients with First Pulmonary Recurrence of Osteosarcoma 4. PHII-66 Phase II Study of Bay for Patient with Imatinib and Sunitinib-Resistant Malignant Gastrointestinal Stromal Tumor (NCI #7028) 5. AEWS02B1 Groupwide Biology and Banking Study for Ewing Sarcoma 11. Urologic Cancers A. Bladder/Urethral Cancer 1. S0337 Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine Versus Saline in Patients with Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer 2. S0353 Phase II Study of Intravesical Gemcitabine in Patients with Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG 3. PHII-76 Phase II Study of VEGF Trap in Patients with Recurrent or Metastatic Transitional Carcinoma of the Urothelium 4. PHII-75 Phase I/II Study of E7389 Halichondrin B Analog in Metastatic Urothelial Tract Cancer and Renal Insufficiency B. Kidney Cancer 1. CTSU E2805 Phase III Randomized, Double-Blind Trial of Adjuvant Sunitinib Versus Sorafenib Versus Placebo in Patients with Resected Renal Cell Carcinoma CTSU E2805 UC Davis Cancer Center ; Sutter Cancer Center (SCC)

8 8 2. M Open-Label, Phase II Study to Evaluate the Efficacy and Tolerability of ABT-869 in Subjects with Advanced Renal Cell Carcinoma (RCC) Who Have Previously Received Treatment With Sunitinib 3. UCDCC#176 Phase II Tumor Metrics in Cancer Therapeutics ( UCD) 4. AREN03B2 Renal Tumors Classification, Biology, and Banking Study II. Hematologic Cancers 1. Leukemia 1. AAML0531 Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg ) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults 2. S0333 Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia with Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy 3. S0605 Phase II Study of Lenalidomide (Revlimid ) (NSC ) for Previously Untreated Non- M3, Deletion 5q Acute Myeloid Leukemia (AML) in Patients Age 60 or Older Who Decline Remission Induction Therapy 4. PHII-73 Phase II Study of VEGF Trap (NSC ) in Patients with MDS (NCI #7518) 5. PHI-57 Phase I and Pharmacodynamic Study of GTI-2040 (NSC , IND 67368) in Acute Leukemias (NCI #7689) 6. UCDCC#196 Reduced Intensity Stem Cell Transplantation (RIST) for Patients with Hematological Malignancies Conditioned with Fludarabine and Busulfan 7. AALL0232 High Risk B-Precursor Acute Lymphoblastic Leukemia 8. S9007 Cytogenetic Studies in Leukemia Patients 2. Lymphoma 1. CALGB/ CTSU Phase III Randomized Study of R-CHOP vs. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas 2. S0016 Phase III Trial of CHOP + Rituximab vs. CHOP + Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for Treatment of Newly Diagnosed Follicular Non- Hodgkin s Lymphomas 3. COG 5971 Randomized Phase III Study for The Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma 4. S0410 Phase II Tandem Autologous Stem Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study) CL201 Phase II Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination with Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia 6. UCDCC#196 Reduced Intensity Stem Cell Transplantation (RIST) for Patients with Hematological Malignancies Conditioned with Fludarabine and Busulfan UCDCC#196 UC Davis Cancer Center ; Sutter Cancer Center (SCC)

9 9 7. UCDCC#197 Phase II Trial of the Combination of Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular NHL (RV 0163) 8. S0601 Phase II Study of Combination Rituximab-CHOP and Bortezomib (Velcade ) (R- CHOP-V) Induction Therapy Followed by Bortezomib Maintenance (VM) Therapy for Patients with Newly Diagnosed Mantle Cell Lymphoma 9. PHI-58 Phase I Study of GX (NSC# ) and Bortezomib in Aggressive Relapsed/Rucurrent Non-Hodgkin's Lymphoma (NCI #7943) 10. S0528 Phase I Study Evaluating the Combination of Lapatinib (GW572016; NSC ; IND-75,093) and Everolimus (RAD001; NSC ; IND-75,093) in Patients with Advanced Solid Tumors 3. Myeloma 1. S0115 Phase II Trial Evaluating Modified High Dose Melphalan (100 mg/m2) and Autologous Peripheral Blood Stem Cell Supported Transplantation for Patients with AL Amyloidosis or High Risk (Greater Than or Equal to Age 70 or Poor Renal Function) Patients with Multiple Myeloma (A BMT Study) 2. S0309 Myeloma Specimen Repository Protocol, Ancillary 3. UCDCC#196 Reduced Intensity Stem Cell Transplantation (RIST) for Patients with Hematological Malignancies Conditioned with Fludarabine and Busulfan UCDCC#196 III. Other Solid Tumors 1. M Phase I/IIA Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies 2. PHI-52 Phase I and Pharmacokinetic Study of Oral 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) in the Treatment of Advanced Solid Tumors 3. PHI-53 Phase I Trial of PXD101 in Combination with 13-cis-Retinoic Acid in Advanced Solid Tumor Malignancies 4. PHI-54 Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients with Malignant Solid Tumors 5. PHI-55 Phase I Study of Halichondrin B Analog (E7389) in Combination with Cisplatin in Advanced Solid Tumors 6. UCDCC#171 Phase I Study of Two Different Schedules of Lapatinib (GW572016) in Combination with Vinorelbine in Advanced Solid Tumors 7. PHI-61 Phase I Study of ABT-888, Carboplatin, and Paclitaxel in Patients With Advanced Solid Malignancies UC Davis Cancer Center ; Sutter Cancer Center (SCC)